DiaGenic ASA: Proposal From the Nomination Committee

Published: May 16, 2013

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

OSLO, Norway--(BUSINESS WIRE)--Regulatory News:

DiaGenic ASA (OSE:DIAG):

Please see the following link for the proposal from the nomination committee in DiaGenic ASA to the Company's General Meeting on 23 May 2013: http://mb.cision.com/Public/115/9414767/b10f0a6d3d40b67f.pdf

About DiaGenic ASA

DiaGenic is an innovative Norwegian diagnostic company that seeks to create value for patients, partners and investors by developing innovative and patient friendly in vitro diagnostic (IVD) products for early detection of diseases. The company’s proprietary concept implies that a disease evokes systemic responses in the blood unique for the disease, and which can be measured by using a blood sample. DiaGenic is a world leader in identifying gene expression signatures in blood and is focused on the development of IVD biomarker products in the field of Alzheimer’s disease. The company protects its technology through an extensive patent portfolio. DiaGenic is listed on the Oslo Stock Exchange. For more information please visit: www.diagenic.com

This information was brought to you by Cision http://news.cision.com


DiaGenic ASA

Paul de Potocki

Chief Executive Officer

Telephone: 47 2324 8950

e-mail: paul.depotocki@diagenic.com

Help employers find you! Check out all the jobs and post your resume.

Back to news